Skip to main content

Table 6 Results from a societal perspective and of scenario analyses

From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Description of scenario VN cost (CHF) SoC cost (CHF) Incremental cost of VN (CHF) VN QALYs SoC QALYs Incremental QALYs of VN ICER (CHF/QALY)
Base-case analysis 901’654 137’252 764’402 18.35 11.62 6.73 113’526
Societal perspective; 80% productivity loss 1,213,557 977,006 236,551 18.35 11.62 6.73 35,132
Societal perspective; 50% productivity loss 1,118,565 694,728 423,837 18.35 11.62 6.73 62,947
VN treatment effect lasts for 7.5 years 907,077 137’252 769’825 14.42 11.62 2.80 275,213
VN treatment effect lasts for 20 years 907,427 137,252 770,175 16.55 11.62 4.93 156,171
VN treatment effect lasts for lifetime 853,424 137,252 716,173 19.05 11.62 7.43 96,384
Health state assignment based on VF only 900,423 137,325 763,097 18.86 14.01 4.86 157,157
Extrapolation for long-term phase: Gompertz 900,394 137,264 763,130 18.28 10.96 7.32 104,198
Extrapolation for long-term phase: Log-logistic 901,457 137,230 764,227 18.38 12.24 6.15 124,339
Extrapolation for long-term phase: Log-normal 901,460 137,229 764,230 18.36 12.40 5.95 128,341
Extrapolation for long-term phase: exponential 894,184 137,038 757,146 18.54 13.28 5.26 143,885
Health state utilities obtained using HUI3 [5] 901,654 137,252 764,402 12.19 4.87 7.32 104,413
Discount rate 0% 1,343,226 600,567 742,659 40.42 21.74 18.68 39’767
Discount rate 5% 833,304 65,380 767,924 12.64 8.67 3.97 193,548
Best seeing eye used to assign health states 900,262 137,282 762,980 18.51 11.47 7.04 108,378
Where no transition observed, assume patients remain in same health state. 901,654 137,252 764,402 18.10 11.52 6.58 116,177
  1. KEY: CHF Swiss franc, HUI3 Health utilities index mark 3, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, SoC standard-of-care, VF visual function, VN voretigene neparvovec